Genmab (CPSE:GMAB) Extends Pipeline Momentum, Is The Valuation Now Too Pricey?

J.P. Morgan upgrades Genmab on cancer drug growth potential

Petosemtamab Trial Results May Change The Case For Genmab Stock

Genmab (GMAB) Stock Forum and Discussion

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

TD Cowen Maintains Buy on Genmab, Raises Price Target to $52

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Genmab shares jump 13% on colorectal cancer drug trial results

European shares hold as markets weigh Iran diplomacy, await c.banks

Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026

Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply

Genmab (NDQ:GMAB): A Royalty Engine That’s Getting More and More Powerful!

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?